T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| 1 |
Broadcom
AVGO
|
$898M |
| 2 |
Danaher
DHR
|
$756M |
| 3 |
Intuit
INTU
|
$719M |
| 4 |
PTC
PTC
|
$567M |
| 5 |
Salesforce
CRM
|
$412M |
Top Sells
| 1 |
CrowdStrike
CRWD
|
$882M |
| 2 |
Spotify
SPOT
|
$761M |
| 3 |
KKR & Co
KKR
|
$607M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
$556M |
| 5 |
Goldman Sachs
GS
|
$547M |
Sector Composition
| 1 | Technology | 24.77% |
| 2 | Healthcare | 20.33% |
| 3 | Industrials | 12.32% |
| 4 | Consumer Discretionary | 11.57% |
| 5 | Financials | 10.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
551
Provident Bancorp
PVBC
$231M
| $8.39M | 0.01% |
823,253
-604,197
| -42% | -$6.16M |
|
552
Grifois
GRFS
$6.74B
| $8.21M | 0.01% |
1,303,596
-714,607
| -35% | -$4.5M |
|
|
553
Goldman Sachs
GS
$227B
| $8M | 0.01% |
17,687
-1,210,191
| -99% | -$547M |
|
554
Douglas Dynamics
PLOW
$772M
| $7.94M | 0.01% |
339,222
-543
| -0.2% | -$12.7K |
|
555
Keurig Dr Pepper
KDP
$39.7B
| $7.61M | ﹤0.01% |
227,672
+95,400
| +72% | +$3.19M |
|
|
CNTA
556
Centessa Pharmaceuticals
CNTA
$2.12B
| $7.53M | ﹤0.01% |
+833,993
| New | +$7.53M |
|
557
Madrigal Pharmaceuticals
MDGL
$9.61B
| $7.19M | ﹤0.01% |
25,644
-17,342
| -40% | -$4.86M |
|
558
BridgeBio Pharma
BBIO
$9.91B
| $7M | ﹤0.01% |
276,369
-1,168,748
| -81% | -$29.6M |
|
559
Nike
NKE
$111B
| $6.94M | ﹤0.01% |
92,080
+36,013
| +64% | +$2.71M |
|
560
Schlumberger
SLB
$53.7B
| $6.68M | ﹤0.01% |
141,562
+79,953
| +130% | +$3.77M |
|
561
Morgan Stanley
MS
$240B
| $6.67M | ﹤0.01% |
68,631
-5,146,784
| -99% | -$500M |
|
562
KLA
KLAC
$115B
| $6.48M | ﹤0.01% |
7,860
-514,021
| -98% | -$424M |
|
563
Lockheed Martin
LMT
$107B
| $6.4M | ﹤0.01% |
13,701
+3,390
| +33% | +$1.58M |
|
564
Winnebago Industries
WGO
$1.02B
| $6.36M | ﹤0.01% |
+117,314
| New | +$6.36M |
|
565
Syndax Pharmaceuticals
SNDX
$1.39B
| $5.83M | ﹤0.01% |
283,827
-2,175,408
| -88% | -$44.7M |
|
566
Stryker
SYK
$151B
| $5.55M | ﹤0.01% |
16,321
-683
| -4% | -$232K |
|
567
S&P Global
SPGI
$165B
| $5.54M | ﹤0.01% |
12,413
+1,440
| +13% | +$642K |
|
568
CSX Corp
CSX
$60.9B
| $5.44M | ﹤0.01% |
162,531
+18,937
| +13% | +$633K |
|
569
Marriott International Class A Common Stock
MAR
$73B
| $5.43M | ﹤0.01% |
22,465
+2,800
| +14% | +$677K |
|
570
PNC Financial Services
PNC
$81.7B
| $5.43M | ﹤0.01% |
34,928
-3,216,229
| -99% | -$500M |
|
571
Zentalis Pharmaceuticals
ZNTL
$128M
| $5.42M | ﹤0.01% |
1,325,491
-1,993,595
| -60% | -$8.15M |
|
572
Zoetis
ZTS
$67.9B
| $5.39M | ﹤0.01% |
31,076
-14,968
| -33% | -$2.6M |
|
|
ANSS
573
DELISTED
Ansys
ANSS
| $5.01M | ﹤0.01% |
+15,576
| New | +$5.01M |
|
574
Nkarta
NKTX
$151M
| $4.78M | ﹤0.01% |
808,566
-546,755
| -40% | -$3.23M |
|
575
Ascendis Pharma
ASND
$12B
| $4.17M | ﹤0.01% |
30,564
-2,538,339
| -99% | -$346M |
|